was successfully added to your cart.


Forxiga (dapagliflozin) 5mg should no longer be used for the treatment of Type 1 Diabetes Mellitus

By November 16, 2021Latest News

AstraZeneca, in agreement with the European Medicines Agency and the [National Competent Authority], has made the following announcement:

Effective 25 October 2021 Forxiga (dapagliflozin) 5mg is no longer authorised for the treatment of patients with type 1 diabetes mellitus (T1DM) and should no longer be used in this population. This is based on Astra Zeneca’s decision to remove the T1DM indication for dapagliflozin 5mg.

If this affects you, then please discuss this with your consultant or healthcare team.


InDependent Diabetes Trust